Eddie Rodriguez Castro, MD
Nephrology · Toa Baja, PRNPI 1760740849
Payments from drug & device makers
Across 915 payments — averaging $646.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$180K
- Amgen$105K
- Bayer$95K
- GSK$71K
- Travere Therapeutics, Inc.$69K
- ANI Pharmaceuticals, Inc.$23K
- plus $49K from 27 others
What the payments were for
- Consulting fees$19,8783%
- Speaking & faculty fees$512,63887%
- Travel & lodging$23,9464%
- Food & beverage$34,6976%
- Education$2560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 288 | $179,880 |
| Amgen(2 entities) | 135 | $105,370 |
| Bayer | 97 | $94,880 |
| GSK | 45 | $70,744 |
| Travere Therapeutics, Inc. | 91 | $68,967 |
| ANI Pharmaceuticals, Inc. | 33 | $22,824 |
| Otsuka America Pharmaceutical, Inc. | 26 | $22,699 |
| Johnson & Johnson | 41 | $17,521 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $1,805 |
| Mallinckrodt Hospital Products Inc. | 15 | $1,121 |
| Boehringer Ingelheim | 29 | $808 |
| Bayer Puerto Rico Inc. | 34 | $756 |
| Novartis | 10 | $628 |
| Calliditas Therapeutics US Inc. | 13 | $517 |
| Vifor Pharma, Inc. | 11 | $475 |
| Novo Nordisk | 11 | $444 |
| Lilly USA, LLC | 8 | $353 |
| Cormedix Inc. | 1 | $261 |
| Boston Scientific | 2 | $218 |
| Scpharmaceuticals Inc. | 2 | $144 |
| Mallinckrodt Enterprises LLC | 1 | $124 |
| Madrigal Pharmaceuticals | 1 | $118 |
| Terumo Medical Corporation | 1 | $117 |
| Medtronic | 1 | $108 |
| Kyowa Kirin, Inc. | 2 | $94 |
| Eli Lilly Export S.A. Puerto Rico Branch | 4 | $89 |
| Bard Peripheral Vascular, Inc. | 1 | $82 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $75 |
| Alnylam Pharmaceuticals Inc. | 1 | $75 |
| Sobi, Inc | 1 | $43 |
| Apellis Pharmaceuticals, Inc. | 2 | $29 |
| Sanofi | 1 | $28 |
| Chiesi USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$591,416 in reported general payments places this provider in the 95th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 903 | $1,095,980 |
| JardianceEmpagliflozin | 283 | $320,312 |
| KerendiaFinerenone | 354 | $284,791 |
| BenlystaBelimumab | 36 | $187,820 |
| OzempicSemaglutide | 160 | $159,973 |
| TrulicityDulaglutide | 71 | $81,103 |
| Xigduo XrDapaglifloz Propaned/Metformin | 55 | $75,534 |
| LokelmaSodium Zirconium Cyclosilicate | 68 | $69,121 |
| RybelsusSemaglutide | 19 | $29,925 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $28,658 |
| JanuviaSitagliptin Phosphate | 18 | $24,090 |
| Sevelamer Carbonate | 132 | $24,032 |
| XareltoRivaroxaban | 23 | $22,313 |
| Calcium Acetate | 201 | $20,189 |
| EliquisApixaban | 23 | $19,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $179,880 | $1,165,101971 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi | $808 | $378,752339 claims |
| BayerKerendia | $94,880 | $284,791354 claims |
| Novo NordiskOzempic, Rybelsus | $444 | $189,898179 claims |
| GSKBenlysta | $70,744 | $187,82036 claims |
| Lilly USA, LLCTrulicity, Humalog | $353 | $87,112113 claims |
| Johnson & JohnsonXarelto | $17,521 | $22,31323 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $22,824 | $87215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Toa Baja
- Ricardo Alicea-GuevaraToa Baja$10K
- Agustin Velazquez PerezToa Baja$5K
- Michelle Cofan HernandezToa Baja$5K
- Angel Delgado GarrasteguiToa Baja$3K
- Luis Diaz CruzToa Baja$3K
- Rafael Burgos CalderonBayamon$394K
- Eugenia Galindo RamosCaguas$360K
- Jose Cangiano-RiveraSan Juan$300K
- Ileana Ocasio MelendezDorado$261K
- William Hurtado-SantiagoMayaguez$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.